Shots:

• NIAID- part of NIH to receive milestones and royalties on sales of N6LS. GSK and NIH to jointly identify & develop broadly neutralizing antibodies (bNAbs) including N6LS for providing the treatment & preventative options for HIV transmission
• ViiV to initiate P-IIa study with material manufactured by the NIAID Vaccine Research Center and will lead to evaluation of efficacy- safety- tolerability- and PK profile of N6LS in adults living with HIV
• N6LS is an antiviral bNAb- designed to bind to a specific site (gp120) on the surface of HIV- preventing its entry into uninfected immune system cells (CD4+ T-cells)- thus the HIV replication is halted- and its transmission is prevented

Click here to­ read full press release/ article | Ref: GSK | Image: ViiV Healthcare